Adeno-associated viruses (AAV), which consist of a DNA payload enclosed inside a capsid shell, are regularly employed as vectors for this purpose. However, some capsids can be empty following ...

Underpinning Voyager’s mission is its trademark AAV capsid-discovery platform, Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER). This broadly applicable, functional ...

With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

The biotech is developing a Huntington’s disease (HD) gene therapy based on its proprietary capsid, AAV-DB-3. HD damages the neurons in the striatum, leading Latus to target the deep brain.

In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit. The Vericheck ddPCR Empty-Full Capsid ...

AAV9 is known to have some natural ability to penetrate the blood-brain barrier, and researchers have generated AAV9 capsid variants that efficiently cross the blood-brain barrier and enter neurons in ...

Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, ...

Under the terms of the new agreement, Dyno is responsible for the design and discovery of novel AAV capsids with improved functional properties. Roche in turn is responsible for conducting capsid ...

today announced the launch of the Vericheck ddPCR™ Empty-Full Capsid Kit for the determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) ...